Novo Nordisk's Robust Sales Outlook is Reassuring -- Market Talk

Dow Jones

Feb 05, 2025

0847 GMT - Novo Nordisk's 2025 outlook is reassuring, says Sheena Berry at Quilter Cheviot. The Danish pharmaceutical company expects a robust 16%-24% sales growth for the year, Berry says. Fourth-quarter sales rose 30%, outpacing expectations, although this was partly driven by insulin rebate adjustments, she notes. The performance of key growth drivers, Ozempic and Wegovy, remains strong, with Ozempic meeting expectations and Wegovy slightly underperforming. Novo Nordisk is set to initiate a new CagriSema Phase 3 trial in 2025 and plans to file with regulators in the first quarter of 2026, a slight delay to ensure a secure supply chain. Shares trade 4.5% higher at 619 Danish kroner. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

February 05, 2025 03:47 ET (08:47 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2509247456"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2509247456\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2509247456?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-05 16:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2509247456","market":"sg","top_or_hot":-1,"title":"Novo Nordisk's Robust Sales Outlook is Reassuring -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0847 GMT - Novo Nordisk's 2025 outlook is reassuring, says Sheena Berry at Quilter Cheviot. The Danish pharmaceutical company expects a robust 16%-24% sales growth for the year, Berry says. Fourth-quarter sales rose 30%, outpacing expectations, although this was partly driven by insulin rebate adjustments, she notes. The performance of key growth drivers, Ozempic and Wegovy, remains strong, with Ozempic meeting expectations and Wegovy slightly underperforming. Novo Nordisk is set to initiate a new CagriSema Phase 3 trial in 2025 and plans to file with regulators in the first quarter of 2026, a slight delay to ensure a secure supply chain. Shares trade 4.5% higher at 619 Danish kroner. (dominic.chopping@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 05, 2025 03:47 ET (08:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk's Robust Sales Outlook is Reassuring -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk's Robust Sales Outlook is Reassuring -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-05 16:47</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0847 GMT - Novo Nordisk's 2025 outlook is reassuring, says Sheena Berry at Quilter Cheviot. The Danish pharmaceutical company expects a robust 16%-24% sales growth for the year, Berry says. Fourth-quarter sales rose 30%, outpacing expectations, although this was partly driven by insulin rebate adjustments, she notes. The performance of key growth drivers, Ozempic and Wegovy, remains strong, with Ozempic meeting expectations and Wegovy slightly underperforming. Novo Nordisk is set to initiate a new CagriSema Phase 3 trial in 2025 and plans to file with regulators in the first quarter of 2026, a slight delay to ensure a secure supply chain. Shares trade 4.5% higher at 619 Danish kroner. (dominic.chopping@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 05, 2025 03:47 ET (08:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2509247456","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2509247456","pubTimestamp":1738745220,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0847 GMT - Novo Nordisk's 2025 outlook is reassuring, says Sheena Berry at Quilter Cheviot. The Danish pharmaceutical company expects a robust 16%-24% sales growth for the year, Berry says. Fourth-quarter sales rose 30%, outpacing expectations, although this was partly driven by insulin rebate adjustments, she notes. The performance of key growth drivers, Ozempic and Wegovy, remains strong, with Ozempic meeting expectations and Wegovy slightly underperforming. Novo Nordisk is set to initiate a new CagriSema Phase 3 trial in 2025 and plans to file with regulators in the first quarter of 2026, a slight delay to ensure a secure supply chain. Shares trade 4.5% higher at 619 Danish kroner. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"诺和诺德强劲的销售前景令人放心——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"0847 GMT - Novo Nordisk's 2025 outlook is reassuring, says Sheena Berry at Quilter Cheviot. The Danish pharmaceutical company expects a robust 16%-24% sales growth for the year, Berry says. Fourth-quarter sales rose 30%, outpacing expectations, although this was partly driven by insulin rebate adjustments, she notes. The performance of key growth drivers, Ozempic and Wegovy, remains strong, with Ozempic meeting expectations and Wegovy slightly underperforming. Novo Nordisk is set to initiate a new CagriSema Phase 3 trial in 2025 and plans to file with regulators in the first quarter of 2026, a slight delay to ensure a secure supply chain. Shares trade 4.5% higher at 619 Danish kroner. (dominic.chopping@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 05, 2025 03:47 ET (08:47 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}